Since Ian Read became Pfizer Inc.’s leader, he’s shed two non-drug businesses, reorganized the company into three separate units and pursued the largest merger in the history of the pharmaceutical industry.
For three years, Pfizer Inc. Chief Executive Officer Ian Read has been firing people, trimming research initiatives and shedding businesses in a less-is-more strategy designed to cut back the excesses from a decade of megamergers. No more.
Pfizer Inc., the world’s biggest drugmaker, faces competition to its $3 billion arthritis pill Celebrex in May after a federal judge invalidated a patent that could have delayed generic versions of the medicine.
Eli Lilly & Co.’s experimental drug dulaglutide was as good at controlling Type 2 diabetes as the leading treatment in a clinical trial, providing Lilly with a potential marketing advantage as it seeks to gain approval of the medicine.
Pfizer Inc., the world’s biggest drugmaker, faces competition to its $3 billion arthritis pill Celebrex in May after a federal judge invalidated a patent that would have extended protection through December 2015.
Merck & Co., the second-biggest U.S. drugmaker by sales, will work with three other drugmakers to find the most-promising combination treatments for its top pipeline prospect, an immune system-based cancer medicine.